Pharmacology Core

临床前和临床药理学的作用是最大限度地提高已确定的 候选人，或快速排除一个可能不成功的候选人进入进一步的测试。这个 药理学核心(核心B)的主要目标是为Martin Deianey的研究人员提供 合作根除HLV-1感染与药理学专业知识研究治疗策略 减少潜伏的病毒池和动物模型系统，并评估病毒的药理学基础 人类的坚持不懈。药理学核心将协调对化学图书馆的访问，协助铅 候选扩大生产规模，协调动物毒理学研究，分析药物生物基质 浓度(抗逆转录病毒和诱导/根除化合物)，提供药代动力学/ 药效学(PK/PD)建模以选择最佳剂量和剂量频率，并进行试验 模拟以优化设计和抽样策略。这个核心将参与药物的方方面面 确定和推进铅诱导/根除候选者的进展情况。核心领导力 团队(Kasshba博士和Tan博士)在临床前和临床方面拥有20多年的综合经验 药理学、分析化学和核心管理，非常适合支持 合作实验室。这导致了一个核心，它结合了学术和行业资源来协同 强项。

The role of Preclinical and Clinical Pharmacology is to maximize the likelihood of success of an identified candidate, or to quickly remove a likely unsuccessful candidate from progressing into further testing. The primary objective of the Pharmacology Core (Core B) is to provide the investigators of the Martin Deianey Collaboratory to Eradicate HlV-1 Infection with the pharmacologic expertise to study therapeutic strategies that reduce the latent viral pool and animal model systems, and to evaluate the pharmacologic basis of viral persistence in humans. The Pharmacology Core will coordinate access to chemical libraries, assist with lead candidate production scale-up, coordinate animal toxicology studies, analyze biological matrices for drug concentrations (both antiretroviral and induction/eradication compounds), provide pharmacokinetic/ pharmacodynamic (PK/PD) modeling for optimal dose and dose frequency selection, and perform trial simulation to optimize design and sampling strategies. This Core will participate in all aspects of drug development for identifying and progressing lead induction/eradication candidates. The Core leadership team (Drs. Kashuba and Tan) has over 20 years combined experience in preclinical and clinical pharmacology, analytical chemistry, and Core management, and are well-suited to support the projects in the Collaboratory. This results in a Core which combines academic and industry resources to synergize strengths.